Spectrum Pharmaceuticals Inc. (SPPI) was among the biggest gainers on the Russell 2000 for Wednesday January 20 as the stock popped 5.52% to $4.97, representing a gain of $0.26 per share. Some 797,284 shares traded hands on 7,497 trades, compared with an average daily volume of 1.16 million shares out of a total float of 67.34 million. The stock opened at $4.63 and traded with an intraday range of $4.99 to $4.56.
After today's gains, Spectrum Pharmaceuticals Inc. reached a market cap of $334.68 million. Spectrum Pharmaceuticals Inc. has had a trading range between $7.74 and $4.62 over the last year, and it had a 50-day SMA of $5.52 and a 200-day SMA of $6.28.
Spectrum Pharmaceuticals Inc is a biotechnology company with fully integrated commercial and drug development operations with a primary focus on oncology and hematology.
Spectrum Pharmaceuticals Inc. is based out of Henderson, NV and has some 241 employees. Its CEO is Rajesh C. Shrotriya.
For a complete fundamental analysis analysis of Spectrum Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for SPPI. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer